newsfilter
← Latest News
GlobeNewswire·

Publication in Cell Shows That Vaccitech's SNAPvax™ Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel "Vax-Innate" Paradigm

Vaccitech collaborators at NIH's Vaccine Research Center demonstrate that IV administration of SNAPvax in animal models activates two key pathways leading to improved T cell mediated tumor killing in a paradigm referred